Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
| Autor: | van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2018 102:40-48 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect